The weight-loss market is booming in Western countries as the Ozempic trend has led to many people opting for diabetes drugs to lose weight. Eli Lilly is planning to launch Mounjaro, a diabetes drug that can be used for losing weight. The drug contains an active ingredient called Tirzepatide which helps in the treatment of type-2 diabetes and weight loss. 

India is a country with a large population and a high obesity rate. It also stands second in the world for most diabetic patients. This is the perfect market for companies like Eli Lilly and Novo Nordisk to launch their drugs here. But the question is, does India need it? India already has world-class generic drug developers that can create the same drug for way more affordable prices. But one more problem with the weight-loss drug can be the promotion of unhealthy lifestyles. Indians are already suffering from a lack of physical activities and now with the legit weight loss drugs floating in the market, it raises a big question on the safety and side effects of such medication. 

Lilly recently got approval from the US for its development and sales of the weight loss drug Zepbound. The medication is sold with the name Mounjaro as a diabetic drug in the US, UK and other parts of Europe but is sold as Zepbound for weight loss. These drugs work on controlling the blood sugar level but also slow down digestion and result in less overeating as the body feels full for a longer time. Lilly’s rival Novo Nordisk also has their diabetic and weight-loss drug called Wegovy which is planned to be released in India in 2026. Indian generic drugmakers like Cipla, Lupin, Sun Pharma, and many others are already trying to make a generic version of the drug. 

The weight loss effect of the drug is exploding the market and it is estimated to touch at least 100 Billion dollars by the end of the decade. The scope for such medication to bloom in India is very high and the market is there for both the diabetes and weight loss aspects of the drug.